160 related articles for article (PubMed ID: 32620306)
1. Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model.
Shankara Narayanan JS; Vicente DA; Ray P; Chai LF; Erdem S; Carr MJ; Capacio BA; Cox BF; Jaroch DB; Katz SC; White RR
Surgery; 2020 Sep; 168(3):448-456. PubMed ID: 32620306
[TBL] [Abstract][Full Text] [Related]
2. Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model.
Capacio BA; Shankara Narayanan JS; Vicente DA; Liu Y; LaPorte JP; Cox BF; Jaroch DB; Katz SC; White RR
Surgery; 2023 Sep; 174(3):666-673. PubMed ID: 37391328
[TBL] [Abstract][Full Text] [Related]
3. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Knoop RF; Sparn M; Waldmann J; Plassmeier L; Bartsch DK; Lauth M; Hudemann C; Fendrich V
Neoplasia; 2014 Jun; 16(6):463-70. PubMed ID: 24953430
[TBL] [Abstract][Full Text] [Related]
4. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer.
Park K
J Control Release; 2016 Dec; 243():381. PubMed ID: 28024837
[No Abstract] [Full Text] [Related]
6. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
7. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
Hessmann E; Patzak MS; Klein L; Chen N; Kari V; Ramu I; Bapiro TE; Frese KK; Gopinathan A; Richards FM; Jodrell DI; Verbeke C; Li X; Heuchel R; Löhr JM; Johnsen SA; Gress TM; Ellenrieder V; Neesse A
Gut; 2018 Mar; 67(3):497-507. PubMed ID: 28077438
[TBL] [Abstract][Full Text] [Related]
9. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study.
Beane JD; Griffin KF; Levy EB; Pandalai P; Wood B; Abi-Jaoudeh N; Beresnev T; Shutack Y; Webb CC; Avital I; Rudloff U
Invest New Drugs; 2015 Feb; 33(1):109-18. PubMed ID: 25236592
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer.
Tang S; Hang Y; Ding L; Tang W; Yu A; Zhang C; Sil D; Xie Y; Oupický D
Mol Pharm; 2021 Dec; 18(12):4448-4458. PubMed ID: 34699242
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
[No Abstract] [Full Text] [Related]
12. Transport properties of pancreatic cancer describe gemcitabine delivery and response.
Koay EJ; Truty MJ; Cristini V; Thomas RM; Chen R; Chatterjee D; Kang Y; Bhosale PR; Tamm EP; Crane CH; Javle M; Katz MH; Gottumukkala VN; Rozner MA; Shen H; Lee JE; Wang H; Chen Y; Plunkett W; Abbruzzese JL; Wolff RA; Varadhachary GR; Ferrari M; Fleming JB
J Clin Invest; 2014 Apr; 124(4):1525-36. PubMed ID: 24614108
[TBL] [Abstract][Full Text] [Related]
13. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
14. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
15. The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine.
Chen SM; Chieng WW; Huang SW; Hsu LJ; Jan MS
Sci Rep; 2020 Nov; 10(1):20319. PubMed ID: 33230218
[TBL] [Abstract][Full Text] [Related]
16. Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer.
Kramer RM; Russell J; Humm JL
Cancer Biother Radiopharm; 2015 Sep; 30(7):299-304. PubMed ID: 26203552
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
Pham NA; Tsao MS; Cao P; Hedley DW
Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832
[TBL] [Abstract][Full Text] [Related]
18. Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
Bosco G; Guizzon L; Yang Z; Camporesi E; Casarotto A; Bosio C; Mangar D; Chen C; Cannato M; Toniolo L; Garetto G; Nasole E; Bassi C
Anticancer Res; 2013 Nov; 33(11):4827-32. PubMed ID: 24222119
[TBL] [Abstract][Full Text] [Related]
19. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.
Soni KS; Thomas D; Caffrey T; Mehla K; Lei F; O'Connell KA; Sagar S; Lele SM; Hollingsworth MA; Radhakrishnan P; Bronich TK
J Pharmacol Exp Ther; 2019 Sep; 370(3):894-901. PubMed ID: 30683666
[TBL] [Abstract][Full Text] [Related]
20. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Mondal G; Kumar V; Shukla SK; Singh PK; Mahato RI
Biomacromolecules; 2016 Jan; 17(1):301-13. PubMed ID: 26626700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
